AI주식인사이트AI Stock Insight
C

명문제약

017180KOSPI의약품 제조업

41.0 / 100

Reference Date: 2026-06-10

Financial Score14.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 22.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Myungmoon Pharmaceutical operates in two main segments: pharmaceutical/biotech and services. The company generates revenue through the production and distribution of key products such as cholesterol treatment medications. In 2025, consolidated sales reached approximately 195,247 million won, showing growth in both domestic and export markets.

Number of Employees

309people

Average Salary

63.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
23.16Industry Average 11.931.5Point

1.9x industry avg (risky)

PBR
0.43Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE
1.37Industry Average 4.011.0Point

Well below industry avg

Debt Ratio
68.58Industry Average 12.430.0Point

5.5x industry avg (risky)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲7.3% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲177.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -2.6% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,320Won52-week high 1,94552-week low 1,320
1-month return0.0Point

1m -22.49% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral기업지배구조보고서공시2026-05-29
  • Neutral분기보고서 (2026.03)2026-05-15